Reader technique as a source of variability in determining malaria parasite density by microscopy

Abstract Background Accurate identification and quantification of malaria parasites are critical for measuring clinical trial outcomes. Positive and negative diagnosis is usually sufficient for the assessment of therapeutic outcome, but vaccine or prophylactic drug trials require measuring density o...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Maguire Jason D, Muth Sinuon, Wongsrichanalai Chansuda, Barcus Mazie, O'Meara Wendy, Jordan Robert G, Prescott William R, McKenzie F Ellis
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2006
Subjects:
Online Access:https://doi.org/10.1186/1475-2875-5-118
https://doaj.org/article/90abc4a18f65456eb23488a993a17852
Description
Summary:Abstract Background Accurate identification and quantification of malaria parasites are critical for measuring clinical trial outcomes. Positive and negative diagnosis is usually sufficient for the assessment of therapeutic outcome, but vaccine or prophylactic drug trials require measuring density of infection as a primary endpoint. Microscopy is the most established and widely-used technique for quantifying parasite densities in the blood. Methods Results obtained by 24–27 expert malaria microscopists, who had independently read 895 slides from 35 donors, were analysed to understand how reader technique contributes to discrepancy in measurements of parasite density over a wide range of densities. Results Among these 35 donations, standard deviations ranged from 30% to 250% of the mean parasite density and the percent discrepancy was inversely correlated with the mean parasite density. The number of white blood cells indexed and whether parasites were counted in the thick film or thin film were shown to significantly contribute to discrepancy amongst microscopists. Conclusion Errors in microscopy measurements are not widely appreciated or addressed but have serious consequences for efficacy trials, including possibly abandoning promising vaccine candidates.